Yeast Reveal a “Druggable” Rsp5/Nedd4 Network that Ameliorates α-Synuclein Toxicity in Neurons-Reference-Cited by-同舟云学术

Yeast Reveal a “Druggable” Rsp5/Nedd4 Network that Ameliorates α-Synuclein Toxicity in Neurons

Published:2013-11-22 Issue:6161 Volume:342 Page:979-983
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Tardiff Daniel F.¹,Jui Nathan T.²,Khurana Vikram¹³,Tambe Mitali A.⁴,Thompson Michelle L.⁵,Chung Chee Yeun¹,Kamadurai Hari B.⁶,Kim Hyoung Tae⁷,Lancaster Alex K.¹,Caldwell Kim A.⁵,Caldwell Guy A.⁵,Rochet Jean-Christophe⁴,Buchwald Stephen L.²,Lindquist Susan¹⁸

Affiliation:

1. Whitehead Institute for Biomedical Research (WIBR), Cambridge, MA 02142, USA.

2. Department of Chemistry, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USA.

3. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

4. Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.

5. Department of Biological Sciences, University of Alabama, Tuscaloosa, AL 35487, USA.

6. Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN 38018, USA.

7. Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.

8. Howard Hughes Medical Institute (HHMI), Department of Biology, MIT, Cambridge, MA 02139, USA.

Abstract

From Yeast to Therapeutic? Yeast has shown some promise as a model system to generate lead compounds that could have therapeutic potential for the cellular problems associated with neurodegenerative diseases. Along these lines, Tardiff et al. (p. 979 , published online 24 October) and Chung et al. (p. 983 , published online 24 October) describe the results of multiple screens in yeast that lead to the identification of a potential therapeutic compound to combat the cytotoxic affect of α-synuclein accumulation. The compound was able to reverse the pathological hallmarks of Parkinson's disease in cultured neurons derived from patients with α-synuclein–induced Parkinson's disease dementia.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference50 articles.

1. How were new medicines discovered?

2. Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast?

3. Different 8-Hydroxyquinolines Protect Models of TDP-43 Protein, α-Synuclein, and Polyglutamine Proteotoxicity through Distinct Mechanisms

4. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models

5. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models

Cited by 224 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ubiquitin proteasome system and glaucoma: A survey of genetics and molecular biology studies supporting a link with pathogenic and therapeutic relevance;Molecular Aspects of Medicine;2023-12

2. Molecular Mechanisms Underlying Alzheimer’s and Parkinson’s Disease and the Possibility of Their Neutralization;Cell and Tissue Biology;2023-12

3. Tuning Hsp104 specificity to selectively detoxify α-synuclein;Molecular Cell;2023-09

4. Genome-wide CRISPR–Cas9 Knockout Screening Reveals a TSPAN3-mediated Endo-lysosome Pathway Regulating the Degradation of α-Synuclein Oligomers;Molecular Neurobiology;2023-07-21

5. Aptamer Reduces Aggregation of Mutant Huntingtin and Rescues Proteostasis Network in Non-Neuronal and Neuronal Cells;ACS Chemical Neuroscience;2023-06-09